论文部分内容阅读
目的探究多巴丝肼片(美多芭)联合盐酸普拉克索治疗帕金森症的临床疗效。方法 64例帕金森症患者,随机分为对照组和观察组,各32例。对照组单纯采用美多芭治疗,观察组采用美多芭联合盐酸普拉克索治疗,比较两组患者临床疗效和不良反应。结果观察组患者治疗总有效率为93.8%,高于对照组的71.9%,差异具有统计学意义(P<0.05);观察组患者不良反应发生率低于对照组(P<0.05)。结论帕金森症采用美多芭与盐酸普拉克索联合治疗能够有效改善或缓解患者临床症状,不良反应少,治疗效果良好,值得临床推广应用。
Objective To investigate the clinical efficacy of dopahydrazide tablets (metoprolol) combined with pramipexole hydrochloride in the treatment of Parkinson’s disease. Methods Sixty-four patients with Parkinson’s disease were randomly divided into control group and observation group, with 32 cases in each group. The control group was treated with only metoprolol, the observation group was treated with pramipexole hydrochloride and pramipexole hydrochloride, and the clinical efficacy and adverse reactions of the two groups were compared. Results The total effective rate of observation group was 93.8%, higher than 71.9% of control group, the difference was statistically significant (P <0.05). The incidence of adverse reactions in observation group was lower than that of control group (P <0.05). Conclusions Parkinson’s disease combined with pramipexole hydrochloride and pramipexole hydrochloride can effectively improve or alleviate the clinical symptoms of patients, with fewer adverse reactions and good therapeutic effects, which is worthy of clinical application.